GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » Deferred Policy Acquisition Costs

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Deferred Policy Acquisition Costs


View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP
Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.